Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
285 stopped studies mapped to Acute Lymphoblastic Leukemia and descendants · 88% state a reason
Over the 285 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06738368 | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or… | Phase 2 | suspended | Dec 17, 2024 | University of Washington | Safety Review | Safety / toxicity |
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | AO GENERIUM | The sponsor discontinued the development of the drug for reasons other than safety. | Safety / toxicity |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | N/A | suspended | May 20, 2024 | Case Comprehensive Cancer Center | Voluntary hold by PI | Other (stated, no rule matched) |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | — | suspended | Jan 2, 2026 | Washington University School of Medicine | Admin review | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | Phase 1 | terminated | Mar 2, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | Phase 1 | terminated | Mar 14, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | M.D. Anderson Cancer Center | \<75% participants | Other (stated, no rule matched) |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… | Phase 1 | terminated | Apr 29, 2026 | ImmunityBio, Inc. | Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Safety / toxicity |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2024 | Kevin McNerney | The trial has been stopped pending FDA approval of modifications to the trial protocol. | Other (stated, no rule matched) |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute… | Phase 2 | terminated | Apr 4, 2018 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult… | Phase 1 / Phase 2 | terminated | Oct 20, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06447987 | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed… | Phase 1 | suspended | Jun 7, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute… | Phase 1 / Phase 2 | withdrawn | May 14, 2026 | Institute of Hematology & Blood Diseases Hospital, China | drug-associated adverse reactions | Safety / toxicity |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jan 17, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | Phase 2 | withdrawn | Aug 26, 2024 | Institute of Hematology & Blood Diseases Hospital, China | No eligeble patients | Other (stated, no rule matched) |
| NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After… | Phase 1 | withdrawn | Mar 27, 2026 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and… | Phase 2 | terminated | Mar 7, 2022 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma… | Phase 2 | terminated | Feb 27, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute… | Phase 1 / Phase 2 | withdrawn | Jun 18, 2023 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Phase 1 | withdrawn | Dec 28, 2021 | Ossium Health, Inc. | Change in Study Design | Other (stated, no rule matched) |
| NCT04817761 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | Phase 2 / Phase 3 | terminated | Mar 26, 2021 | Institut de Recherches Internationales Servier | Sponsor decision | Sponsor / business decision |
| NCT03913559 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | Phase 2 | terminated | Apr 12, 2019 | St. Jude Children's Research Hospital | Closed due to slow accrual | Enrollment / accrual |
| NCT05181904 | Gastric Content Ultrasound Monitoring Prior to Extubation in Critically Ill Children(GastrExtub) | — | terminated | Jan 10, 2022 | Hospices Civils de Lyon | Patient enrollment difficulties | Enrollment / accrual |
| NCT04049383 | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL(CAR-20/19-T) | Phase 1 | terminated | Aug 8, 2019 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic… | Phase 1 / Phase 2 | terminated | Oct 9, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent… | Phase 2 | terminated | Jul 19, 2022 | M.D. Anderson Cancer Center | The sponsor requested termination due to internal reprioritization of resources. | Other (stated, no rule matched) |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With…(ISAKIDS) | Phase 2 | terminated | Mar 4, 2019 | Sanofi | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due… | Safety / toxicity |
| NCT03564678 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab… | Phase 2 | terminated | Jun 21, 2018 | M.D. Anderson Cancer Center | PI Request. Slow accrual and lack of clinical interest | Enrollment / accrual |
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at… | N/A | suspended | Oct 15, 2024 | Children's Oncology Group | All potential pilot phase pts have been enrolled. | Enrollment / accrual |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic…(B-ALL) | Phase 1 / Phase 2 | withdrawn | Aug 24, 2023 | Juventas Cell Therapy Ltd. | Sponsor changed product development plan | Other (stated, no rule matched) |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | N/A | withdrawn | Aug 1, 2023 | Neena Kapoor, M.D. | No funding available. | Funding |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | N/A | withdrawn | Aug 28, 2023 | University of Texas at Austin | The logistics of the study made it too challenging to conduct within a pediatric setting. | Other (stated, no rule matched) |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and… | Phase 1 | withdrawn | Aug 30, 2022 | Janssen Research & Development, LLC | Business Decision | Sponsor / business decision |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Study was closed early due to low accrual and lack of response. | Enrollment / accrual |
| NCT05292898 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With… | Phase 1 | terminated | Mar 23, 2022 | Institute of Hematology & Blood Diseases Hospital, China | Achieve the proof of concept | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | Phase 2 | terminated | Sep 21, 2020 | Michael Burke | poor accrual | Enrollment / accrual |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Phase 1 | terminated | Sep 18, 2017 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials